在 SARS-CoV-2 奥密克戎 BA.5.2.1.7、XBB 1.5 和 CH.1.1 亚变种不断变化的嗜性中实施埃及 Kelleni 方案的真实世界实践：一种多用途方案。
Real-world practice of the Egyptian Kelleni's protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants: a multi-purpose protocol.
机构信息
Pharmacology Department, College of Medicine, Minia University, Minya, 61111, Egypt.
出版信息
Inflammopharmacology. 2023 Jun;31(3):1559-1560. doi: 10.1007/s10787-023-01180-6. Epub 2023 Mar 16.
Abstract
The Egyptian immune-modulatory Kelleni's protocol, including nitazoxanide as an integral component, is being safely and effectively practiced to manage SARS-CoV-2, RSV, influenza infections in pediatric, adult and pregnant patients with negligible requirements for the relatively expensive diagnostic molecular tests. Most recently, Kelleni's protocol is being likewise used to manage potential norovirus infection which is currently confused with SARS-CoV-2 Omicron new enterotropic subvariants and the antihistaminic loratadine has been co-administered in selected patients. Notably, Africa has the least mandates, restrictions and SARS-CoV-2 vaccination rates and yet the least COVID-19 mortality.
摘要
埃及的免疫调节 Kelleni 方案，包括硝唑尼特作为一个组成部分，正在安全有效地用于管理 SARS-CoV-2、RSV、流感感染，儿科、成人和孕妇患者的相对昂贵的诊断分子检测需求可忽略不计。最近，Kelleni 方案也被用于管理潜在的诺如病毒感染，目前这种感染与 SARS-CoV-2 奥密克戎新肠嗜性亚变种相混淆，并且在选定的患者中联合使用了抗组胺药氯雷他定。值得注意的是，非洲的强制要求、限制和 SARS-CoV-2 疫苗接种率最低，但 COVID-19 死亡率最低。
相似文献
1
Real-world practice of the Egyptian Kelleni's protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants: a multi-purpose protocol.在 SARS-CoV-2 奥密克戎 BA.5.2.1.7、XBB 1.5 和 CH.1.1 亚变种不断变化的嗜性中实施埃及 Kelleni 方案的真实世界实践：一种多用途方案。
Inflammopharmacology. 2023 Jun;31(3):1559-1560. doi: 10.1007/s10787-023-01180-6. Epub 2023 Mar 16.
2
The African Kelleni's roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one.非洲使用硝唑尼特和广谱抗菌药物来避免重新回到 COVID-19 原点的路线图。
Inflammopharmacology. 2023 Dec;31(6):3335-3338. doi: 10.1007/s10787-023-01263-4. Epub 2023 Jun 16.
3
NSAIDs and Kelleni's protocol as potential early COVID-19 treatment game changer: could it be the final countdown?非甾体抗炎药和 Kelleni 方案作为 COVID-19 早期治疗的潜在改变者：这会是最终倒计时吗？
Inflammopharmacology. 2022 Feb;30(1):343-348. doi: 10.1007/s10787-021-00896-7. Epub 2021 Nov 25.
4
Real-life practice of the Egyptian Kelleni's protocol in the current tripledemic: COVID-19, RSV and influenza.埃及凯莱尼方案在当前新冠、呼吸道合胞病毒和流感三重疫情中的实际应用。
J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.12.007. Epub 2022 Dec 10.
5
Applications of peptide-functionalized or unfunctionalized selenium nanoparticles for the passivation of SARS-CoV-2 variants and the respiratory syncytial virus (RSV).肽功能化或非功能化硒纳米粒子在 SARS-CoV-2 变体和呼吸道合胞病毒（RSV）的钝化中的应用。
Colloids Surf B Biointerfaces. 2024 Jan;233:113638. doi: 10.1016/j.colsurfb.2023.113638. Epub 2023 Nov 9.
6
Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination.尽管基于原型的疫苗接种反复进行，但在 BA.5/ BF.7 突破性感染后，针对奥密克戎亚变种的中和作用随着病毒进化和老化而减弱。
Emerg Microbes Infect. 2023 Dec;12(2):2249121. doi: 10.1080/22221751.2023.2249121. Epub 2023 Sep 5.
7
COVID-19 mortality paradox (United States Africa): Mass vaccination early treatment.新冠病毒疾病（COVID-19）死亡率悖论（美国与非洲）：大规模疫苗接种与早期治疗
World J Exp Med. 2024 Mar 20;14(1):88674. doi: 10.5493/wjem.v14.i1.88674.
8
Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.鼻腔内接种奥密克戎疫苗可对 SARS-CoV-2 变体产生广泛的黏膜和全身免疫。
Signal Transduct Target Ther. 2023 Apr 17;8(1):167. doi: 10.1038/s41392-023-01423-6.
9
SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.严重急性呼吸综合征冠状病毒2型奥密克戎XBB亚变体在老年人群中表现出增强的融合性和显著的免疫逃逸能力，但对泛冠状病毒融合抑制剂高度敏感。
J Med Virol. 2023 Mar;95(3):e28641. doi: 10.1002/jmv.28641.
10
Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.儿童感染 SARS-CoV-2 或接种疫苗后对奥密克戎 BQ.1、BQ.1.1 和 XBB.1 变异株的中和作用。
Nat Commun. 2023 Dec 1;14(1):7952. doi: 10.1038/s41467-023-43152-y.
引用本文的文献
1
COVID-19 mortality paradox (United States Africa): Mass vaccination early treatment.新冠病毒疾病（COVID-19）死亡率悖论（美国与非洲）：大规模疫苗接种与早期治疗
World J Exp Med. 2024 Mar 20;14(1):88674. doi: 10.5493/wjem.v14.i1.88674.
2
Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach.将二甲双胍重新用于治疗特发性或长新冠耳鸣：采用病理生理学和药理学方法进行自我报告。
Inflammopharmacology. 2024 Apr;32(2):945-948. doi: 10.1007/s10787-023-01421-8. Epub 2024 Jan 31.
3
The African Kelleni's roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one.非洲使用硝唑尼特和广谱抗菌药物来避免重新回到 COVID-19 原点的路线图。
Inflammopharmacology. 2023 Dec;31(6):3335-3338. doi: 10.1007/s10787-023-01263-4. Epub 2023 Jun 16.
本文引用的文献
1
Real-life practice of the Egyptian Kelleni's protocol in the current tripledemic: COVID-19, RSV and influenza.埃及凯莱尼方案在当前新冠、呼吸道合胞病毒和流感三重疫情中的实际应用。
J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.12.007. Epub 2022 Dec 10.
2
NSAIDs and Kelleni's protocol as potential early COVID-19 treatment game changer: could it be the final countdown?非甾体抗炎药和 Kelleni 方案作为 COVID-19 早期治疗的潜在改变者：这会是最终倒计时吗？
Inflammopharmacology. 2022 Feb;30(1):343-348. doi: 10.1007/s10787-021-00896-7. Epub 2021 Nov 25.
3
Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis.检测氯雷他定和地氯雷他定对 SARS-CoV-2 刺突假病毒包被的抑制作用。
Chem Biol Interact. 2021 Apr 1;338:109420. doi: 10.1016/j.cbi.2021.109420. Epub 2021 Feb 18.
4
Norovirus gastroenteritis successfully treated with nitazoxanide.硝唑尼特成功治疗诺如病毒胃肠炎。
J Infect. 2011 Nov;63(5):394-7. doi: 10.1016/j.jinf.2011.08.002. Epub 2011 Aug 9.
Zotero 插件